Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on August 07, 2019, 10:31:56 am

Title: Entry Inhibitor Could Potentially Cure Hepatitis B and D
Post by: Hep Editors on August 07, 2019, 10:31:56 am
Bulevirtide, formerly known as Myrcludex B, in combination with pegylated interferon, suppressed hepatitis delta virus (HDV) and led to a functional cure of hepatitis B virus (HBV) in some people living with HBV/HDV dual infection, according to a presentation at the 2019 International Liver Congress in Vienna.

HBV is difficult to treat in part because it produces cccDNA (covalently closed circular DNA), a genetic blueprint of the virus that can lie dormant in liver cells and evade both the immune system and standard therapy. Nucleoside/nucleotide antivirals such as Viread (tenofovir disiproxil fumarate), Vemlidy (tenofovir alafenamide) and Baraclude (entecavir) can suppress HBV replication long term during treatment, but they don’t eliminate the virus and usually do not lead to a cure, as indicated by hepatitis B surface antigen (HBsAg) loss and seroconversion.

Read more...
https://www.hepmag.com/article/entry-inhibitor-potentially-cure-hepatitis-b-d